Spinal Muscular Atrophy (SMA) Treatment Market Register a CAGR of 12.9% by 2025: Grand View Research, Inc.

Posted on 2019-04-01 by researchinsights in Healthcare // 0 Comments

San Francisco, United States, 2019-April-01 — /EPR Network/ —

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost the market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market

Further key findings from the study suggest:

The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
Based on disease type, type 1 accounted for the largest revenue share owing to rising incidence of type 1 SMA
By treatment, the drug segment accounted for the largest revenue share in 2017
North America will retain its lead as the largest regional market; however Asia Pacific is anticipated to register the fastest CAGR over the forecast period
Themarket is presently led by Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post 2020

Related Report of Pharmaceuticals:

Grand View Research has segmented the global spinal muscular atrophy treatment market on the basis of disease type, treatment, route of administration, and region:

SMA Treatment Disease Type Outlook (Revenue, USD Million, 2015 – 2025)

Type 1
Type 2
Type 3
Type 4

SMA Treatment Outlook (Revenue, USD Million, 2015 – 2025)

Gene Therapy
Drug
- Spinraza
- RG6083 (Olesoxime)
- RG7916

SMA Treatment Route of Administration Outlook (Revenue, USD Million, 2015 – 2025)

Oral
Intrathecal

SMA Treatment Regional Outlook (Revenue, USD Million, 2015 – 2025)

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
Asia Pacific
- Japan
- China
Latin America
- Mexico
- Brazil
Middle East & Africa
- South Africa

Access Press Release of This Research Report by Grand View Research:
www.grandviewresearch.com/press-release/global-spinal-muscular-atrophy-sma-treatment-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Matched content

Editor’s pick